All In Biotech

Drug Trial Radar · NCT01714661

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Last checked: Nov 20, 2026Latest source record: May 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 753 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

753

Actual

Start

Oct 2012

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
FORUM Pharmaceuticals IncIndustry
Sponsor type
Industry
Collaborators
Syneos Health; NeuroCog Trials, Inc.
First posted
Oct 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions

  • Schizophrenia
  • Impaired Cognition

Interventions

  • EVP-6124Drug

    Arms 1, 2

  • PlaceboDrug

    Arm 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182Time frame: Baseline to Day 182 or Early Termination
  2. Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182Time frame: Baseline to Day 182 or Early Terminiation
  3. Safety and Tolerability of EVP-6124 or Placebo in Subjects with SchizophreniaTime frame: Screening (Day -42 to Day -15) to Day 182 or Early Terminiation

Locations

94 sites in 13 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Anaheim, California

  • Site not named

    Bellflower, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Culver City, California

  • Site not named

    Downey, California

  • Site not named

    Escondido, California

  • Site not named

    Los Angeles, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    San Diego, California

  • Site not named

    Torrance, California

  • Site not named

    Lauderhill, Florida

  • Site not named

    Miami, Florida

  • Site not named

    North Miami, Florida

  • Site not named

    Orange City, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Wichita, Kansas

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Flowood, Mississippi

  • Site not named

    Creve Coeur, Missouri

  • Site not named

    O'Fallon, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Marlton, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Cedarhurst, New York

  • Site not named

    New York, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Conshohocken, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Dallas, Texas

  • Site not named

    La Plata, Buenos Aires, Argentina

  • Site not named

    Caba, Buenos Aires F.D., Argentina

Showing 40 of 94 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.